Press release
Ocimum Biosolutions offers new solutions in microRNA microarray technology
The epoxide coated microarray slides are spotted with probes which target the miRNAs available in the latest (April 2010) mirBase Release 15 as well as many putative miRNAs. Apart from miRNA microarray chips, Ocimum also offers a complete range of customized services, from miRNA probe/chip design to suit specific experiments to end-to-end chip-to-analysis services.
Ms. Anu Acharya, CEO of Ocimum Biosolutions said “We have been offering the entire gamut of services – miRNA probe design, array design, spotting/printing, isolation, hybridization and bioinformatic analysis – for many years now. With this launch, we have bundled relevant services into a package making it even easier for researchers to work with us.”
She further added “With multiple arrays per slide, researchers will be able to perform multiple hybridization experiments per slide, making the OciChip™ miRNA kits very cost-effective compared to other providers.”
About miRNA Microarrays
miRNAs are small non-protein-coding RNA molecules that play a crucial role in development and life cycle of humans, animals and plants. They function as global regulators of gene expression by targeting specific mRNAs and play a significant role in disease manifestation. miRNAs either inhibit translation or promote mRNA degradation. miRNAs can also be hybridized to microarrays, slides or chips with probes to hundreds or thousands of miRNA targets, so that relative levels of miRNAs can be determined in different samples.
For more information, please visit www.ocimumbio.com.
For queries related to this press release, please write to vinay.k@ocimumbio.com.
About Ocimum Biosolutions
Ocimum Biosolutions is a global integrated genomic services company with operations in Hyderabad, India and Gaithersburg, MD (Gene Logic). We provide comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Our distinct platform "Research as a Service" (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using our proprietary databases and providing data and bioinformatic analysis. We have been chosen as a global preferred outsourcing provider for more than 75% of top 25 pharma and biotech companies plus leading research institutes. Our partners recognize our expertise for understanding disease mechanisms in correlation with discovery, prioritization of gene targets and biomarkers, and sample analysis for clinical studies
Dhanya menon
Communication manager
ocimum Biosolutions
6th floor,Road No 1, Banjara Hills
Hyderabad, Andhra Pradesh 500034
India
Phone :040 66986700
email: dhanya.m@ocimumbio.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ocimum Biosolutions offers new solutions in microRNA microarray technology here
News-ID: 137514 • Views: …
More Releases from Ocimum Biosolutions
Sciantis™ – Ocimum Biosolutions unveils its new software product to handle B …
cimum Biosolutions announces release of its new software product, Sciantis™, a lab process and data management platform for biologics labs. Sciantis™ helps Labs to manage Biologics development process, automate data capturing and support lab Analytics needs.
Mr. Subash Lingareddy, CFO, President of Ocimum Biosolutions, said, “Sciantis™ is our new software offering to serve Biologics companies in improving their development process and data management. This software also serves…
Ocimum Biosolutions Is Winner of Bioexcellence Award ( Bioinformatics and System …
Hyderabad, Andhra Pradesh, India, February 07th, 2012: The Jury of Industry experts constituted by ABLE has declared Ocimum Biosolutions as a Bioexcellence Award winner at Bio INDIA BIO 2012 event under Bioinformatics & Systems Biology Category.
Ms. Anuradha Acharya, CEO of Ocimum Biosolutions said, “Systems Biology and Bioinformatics will be the backbone of future therapeutics and diagnostics. At Ocimum we are focusing our efforts in these areas to meet the needs of the…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
